Breaking News Instant updates and real-time market news.

TSLA

Tesla

$219.14

-0.08 (-0.04%)

, F

Ford

$10.17

0.265 (2.68%)

10:25
06/27/19
06/27
10:25
06/27/19
10:25

Fly Intel: Top five analyst initiations

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Tesla (TSLA) initiated with an Underperform at Credit Suisse while Ford (F) and General Motors (GM) initiated with an Outperform. 2. Take-Two (TTWO) initiated with a Buy at SunTrust. 3. Infinity Pharmaceuticals (INFI) initiated with an Outperform at Oppenheimer. 4. Nomad Foods (NOMD) initiated with a Buy at Goldman Sachs. 5. Schlumberger (SLB) initiated with a Buy at Gabelli. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

TSLA

Tesla

$219.14

-0.08 (-0.04%)

F

Ford

$10.17

0.265 (2.68%)

GM

General Motors

$38.47

0.33 (0.87%)

TTWO

Take-Two

$112.01

0.44 (0.39%)

INFI

Infinity Pharmaceuticals

$1.73

0.05 (2.98%)

NOMD

Nomad Foods

$20.43

0.09 (0.44%)

SLB

Schlumberger

$39.00

-0.05 (-0.13%)

  • 03

    Jul

  • 19

    Jul

  • 24

    Jul

  • 01

    Aug

  • 12

    Aug

  • 27

    Aug

  • 23

    Oct

  • 13

    Nov

TSLA Tesla
$219.14

-0.08 (-0.04%)

06/27/19
LEHM
06/27/19
NO CHANGE
Target $150
LEHM
Underweight
Barclays boosts Tesla delivery forecast, still predicts 'ongoing losses'
Barclays analyst Brian Johnson raised his Q2 delivery forecast for Tesla to 85,000 from 75,000 to reflect the quarter-end push hinted at in leaked Elon Musk emails as well as a likely subsidy-fueled boost in Canada. While we recognizing the "swing trade" in Tesla shares returned, the analyst expects the stock now reflects a delivery beat. He reiterates an Underweight rating on the name with a $150 price target. Johnson still predicts Tesla will post "ongoing losses."
06/27/19
FBCO
06/27/19
INITIATION
Target $189
FBCO
Underperform
Credit Suisse starts Tesla at Underperform, sees 'niche automaker'
Credit Suisse analyst Dan Levy last night initiated coverage of Tesla (TSLA) with an Underperform rating and $189 price target. The stock closed yesterday down 49c to $219.27. While Tesla currently leads in areas that will likely define the future of car making, the company faces "risks ahead" and is "likely to settle as a niche automaker," Levy tells investors in a research note. Volkswagen's (VWAGY) "strong push" on electric vehicles highlights the competition Tesla faces from larger, better capitalized players, according to the analyst. He believes Tesla lacks the same scale as other automakers and that the company has struggled with the basic "processes" of the auto industry. If Tesla can't maintain "healthy" margins, then its edge in the differentiating aspects of the auto business will be a "moot point," says Levy.
06/26/19
FBCO
06/26/19
INITIATION
Target $189
FBCO
Underperform
Tesla initiated with an Underperform at Credit Suisse
Credit Suisse initiated Tesla with an Underperform and $189 price target.
06/26/19
WEDB
06/26/19
NO CHANGE
Target $230
WEDB
Neutral
Tesla unlikely to hit aggressive delivery target, says Wedbush
In the midst of the final week of Q2 for Tesla, Wedbush analyst Daniel Ives believes all eyes on the Street will be focused on whether the company can deliver enough vehicles over the goal line in the coming days to hit its aggressive target for 90k-100k units, which he sees as an unlikely event. As such, the analyst is lowering his unit delivery numbers for the quarter from 88k to 84K units to better reflect his view of demand this quarte. Ives continues to believe the biggest overhang around the story is Tesla's ability to hit its overall unit guidance for 2019 of 360k to 400k units as this will be the telling tale of demand trends as Tesla is now a "demand story" rather than a production story. Hitting the 360k-400k unit demand guidance for 2019 is going to be an "Everest-like task" opinion as 350k is likely "the line in the sand," he contends, adding that hitting 275k Model 3 delivery units for the year would be viewed as a success and ultimately put the company on more stable ground heading into 2020. Ives has a Neutral rating and $230 price target on the shares.
F Ford
$10.17

0.265 (2.68%)

06/27/19
06/27/19
INITIATION
Target $13

Outperform
Credit Suisse bullish on Ford, initiates with an Outperform
As previously reported, Credit Suisse analyst Dan Levy initiated Ford with an Outperform rating and $13 price target. The analyst acknowledges that Ford faces a number of risks ahead, as it redesigns its business to address profitability, while concurrently pursuing a longer-term reimagining of the business. Yet he sees upside for the stock, as there have been early signs of improvement with more to come.
05/15/19
MSCO
05/15/19
NO CHANGE
MSCO
Tariff delay a 'modest positive' for automakers, says Morgan Stanley
Morgan Stanley analyst Michael Zezas called media reports indicating that the U.S. plans to delay auto tariffs by up to 6 months a "modest positive" for the automaking group, stating that extra time somewhat reduces the probability of tariffs going into place but that the core impasse between the U.S. and EU - namely whether or not to include agricultural issues in negotiations - still remains and is the real driver of the tariff tension. The analyst, who noted that the U.S. retains the option to implement tariffs at any point within the 180 day delay, said he still thinks auto tariffs are likely to go into effect later this year. Publicly traded automakers that moved up following the headlines regarding the delay decision include Daimler AG (DDAIF), Fiat Chrysler (FCAU), Ford (F), General Motors (GM), Honda (HMC), Nissan (NSANY), Toyota (TM) and Volkswagen (VWAGY).
06/13/19
GSCO
06/13/19
NO CHANGE
Target $13
GSCO
Buy
Ford recent pullback a buying opportunity, says Goldman Sachs
Goldman Sachs analyst David Tamberrino recommends using the recent pullback in shares of Ford Motor as a buying opportunity. He raised his price target for the shares to $13 from $12 and reiterates a Buy rating on the name. Near-term catalysts from European restructuring actions "can help crystallize" upside in Ford shares, Tamberrino tells investors in a research note. The analyst believes investors will begin to start "underwriting improvement" in the company's European region as restructuring actions come to fruition. Tamberrino sees over 38% total return potential to Ford shares.
06/26/19
FBCO
06/26/19
INITIATION
Target $13
FBCO
Outperform
Ford initiated with an Outperform at Credit Suisse
Credit Suisse initiated Ford with an Outperform and $13 price target.
GM General Motors
$38.47

0.33 (0.87%)

05/15/19
05/15/19
NO CHANGE

Trump plans to delay imposing tariffs on auto imports, Bloomberg reports
Publicly traded companies in the space include Daimler AG (DDAIF), Fiat Chrysler (FCAU), Ford (F), General Motors (GM), Honda (HMC), Nissan (NSANY), Toyota (TM), Volkswagen (VWAGY) and Tesla (TLSA).
06/26/19
FBCO
06/26/19
INITIATION
Target $48
FBCO
Outperform
General Motors initiated with an Outperform at Credit Suisse
Credit Suisse initiated General Motors with an Outperform and $48 price target.
06/27/19
06/27/19
INITIATION
Target $48

Outperform
Credit Suisse bullish on General Motors, initiates with an Outperform
As previously reported, Credit Suisse analyst Dan Levy initiated General Motors with an Outperform rating and $48 price target. The analyst believes General Motors is "one of the best players" in his coverage in balancing the "near and far," and offering a compelling narrative on both fronts.
TTWO Take-Two
$112.01

0.44 (0.39%)

06/24/19
SPHN
06/24/19
NO CHANGE
Target $120
SPHN
Overweight
Stephens switches best idea in video games to Electronic Arts
Stephens analyst Jeff Cohen said he is switching his best idea in video games to Electronic Arts (EA) from Take-Two (TTWO) as he sees more near-term catalysts for the former, noting that Apex Legends Season 2 begins on July 2. While not predicting that Apex is going to eclipse Fortnite again as it did in February, Cohen thinks Fortnite's popularity has "hit a lull" with Season 2 launching at the right time to capture momentum for Apex. The analyst, who sees a bull case scenario where Season 2 generates $150M in revenue for EA, also expects the company to announce a deal to bring Apex to China and mobile, he said. Cohen keeps an Overweight rating on EA shares with a $120 price target.
06/04/19
06/04/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Netflix (NFLX) upgraded to Buy from Hold at Loop Capital with analyst Alan Gould saying Netflix has built an "unstoppable lead" in subscription video streaming while the company's margin opportunity is expanding as it increasingly becomes a content producer, distributor and retailer. 2. Wingstop (WING) upgraded to Buy from Hold at Stifel with analyst Chris O'Cull saying the company's system sales growth will remain in mid to high teens for the foreseeable future and generate higher cash flows from increased average unit volumes thanks to its national advertising and digital ordering initiatives. 3. National Beverage (FIZZ) upgraded to Neutral from Sell at UBS with analyst Sean King citing valuation. 4. Take-Two (TTWO) upgraded to Market Perform from Underperform at BMO Capital with analyst Gerrick Johnson with the threat of an economic downturn, video game stocks will be increasingly seen as "safe havens for investors." 5. Mirati Therapeutics (MRTX) upgraded to Buy from Neutral at Citi with analyst Yigal Nochomovitz saying he believes Mirati's KRAS G12Ci has potential to exceed AMG510's 50% overall response rate in non-small cell lung cancer. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/26/19
RHCO
06/26/19
INITIATION
Target $125
RHCO
Buy
Take-Two initiated with a Buy at SunTrust
SunTrust initiated Take-Two with a Buy and $125 price target.
06/26/19
RHCO
06/26/19
INITIATION
RHCO
Buy
Take-Two initiated with a Buy at SunTrust
SunTrust analyst Matthew Thornton initiated Take-Two with a Buy rating and $125 price target. Thornton said he likes Take-Two as it is a long-term outperformer under its current leadership, and sees the next GTA game, which should land in FY22/CY21, as a "North Star" for the stock that can drive $6-$7 in EPS. He added that this year he sees potential upside driven by games sales such as Borderlands 3, and recurrent revenue.
INFI Infinity Pharmaceuticals
$1.73

0.05 (2.98%)

01/04/19
01/04/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Aveo Pharmaceuticals (AVEO) initiated with an Outperform at Baird. 2. Catalyst Biosciences (CBIO) initiated with Outperform at Oppenheimer. 3. Infinity Pharmaceuticals (INFI) initiated with a Buy at B. Riley FBR. 4. Rockwell Automation (ROK) resumed with a Hold at Deutsche Bank. 5. Dell Technologies (DELL) initiated with a Buy at BofA/Merrill. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
02/26/19
JONE
02/26/19
INITIATION
Target $3.5
JONE
Buy
Infinity Pharmaceuticals initiated with a Buy at JonesTrading
JonesTrading initiated Infinity Pharmaceuticals with a Buy and $3.50 price target.
06/26/19
OPCO
06/26/19
INITIATION
Target $3
OPCO
Outperform
Infinity Pharmaceuticals initiated with an Outperform at Oppenheimer
Oppenheimer initiated Infinity Pharmaceuticals with an Outperform rating and $3 price target.
06/27/19
06/27/19
INITIATION
Target $3

Outperform
Oppenheimer bullish on Infinity Pharmaceuticals, initiates with an Outperform
As previously reported, Oppenheimer analyst Kevin DeGeeter initiated Infinity Pharmaceuticals with an Outperform rating and $3 price target. The analyst notes that emerging evidence regulation of myeloid derived suppressor cells is an attractive strategy for expanding use of immune oncology therapies by reducing immune-suppression in tumor microenvironment, while data from MARIO-1 study demonstrating IPI-549 downregulates MDSCs in checkpoint resistant patients. Further, DeGeeter sees expectation that the Phase I/Ib MARIO-275 study of IPI-549 in combination with nivolumab for checkpoint inhibitor naive urothelial cancer providing proof-of-concept for the strategy by the second half of 2020.
NOMD Nomad Foods
$20.43

0.09 (0.44%)

06/26/19
GSCO
06/26/19
INITIATION
GSCO
Buy
Nomad Foods initiated with a Buy at Goldman Sachs
Goldman Sachs analyst Jason English initiated Nomad Foods with a Buy rating and a $25 price target. The analyst sees the company's restored sales momentum "poised to sustain," expects margins to "revert to growth" in Q3, and believes the base business growth will be suplemented by bolt-on acquisitions.
06/26/19
GSCO
06/26/19
INITIATION
GSCO
Buy
Nomad Foods initiated with a Buy at Goldman Sachs
06/19/19
DADA
06/19/19
INITIATION
Target $26
DADA
Buy
Nomad Foods initiated with a Buy at DA Davidson
DA Davidson analyst Brian Holland initiated Nomad Foods with a Buy rating and a price target of $26. The analyst notes that the impact of a no-deal Brexit is likely to be "negligible" in the near term, with the range of longer-term outcomes also likely being "manageable". Holland adds that over the long term, Nomad Foods is "attractively positioned as a consolidator of choice" in frozen foods across Western Europe, with the stock also working from the currently "depressed" margin levels.
05/23/19
SBSH
05/23/19
INITIATION
Target $24
SBSH
Neutral
Citi starts Nomad Foods at Neutral, says Brexit deadline 'major risk'
Citi analyst David Driscoll initiated coverage of Nomad Foods with a Neutral rating and $24 price target. the company plays in an "attractive" frozen food category and has "solid" growth prospects, but this already reflected in the stock at current valuations, Driscoll tells investors in a research note. Further, the October 31 Brexit deadline creates a layer of near-term uncertainty, and represents a "major risk" to Nomad Foods, adds the analyst.
SLB Schlumberger
$39.00

-0.05 (-0.13%)

04/23/19
RHCO
04/23/19
NO CHANGE
Target $53
RHCO
Buy
Schlumberger price target lowered to $53 from $60 at SunTrust
SunTrust analyst Ken Sill lowered his price target on Schlumberger to $53 after its Q1 results, saying that while its international growth is offsetting a "sluggish" North America, the back half of the year also has "low visibility". The analyst adds that his new implied multiple of 11.1-times enterprise value to expected FY20 EBITDA is above the average forward multiple of 10.6-times over the past 10 years, it is also below the longer term average annual high of 12.7-times. Longer term, Sill keeps his Buy rating on Schlumberger, stating that its increased near-term leverage to North American activity should lead to sustainable long-term growth.
05/15/19
RBCM
05/15/19
NO CHANGE
Target $51
RBCM
Outperform
Schlumberger price target lowered to $51 from $58 at RBC Capital
RBC Capital analyst Kurt Hallead lowered his price target on Schlumberger to $51 to reflect the "fine tuning" of corporate expense estimate to percentage of revenue from previously assumed flat levels, also lowering his FY19 and FY20 EPS view by 3c and 9c to $1.55 and $2.05 as a result. The analyst maintains his Outperform rating however, saying the stock remains a "core through-cycle holding" for large-cap energy investors and anticipating an improvement in the company's international market dynamics.
06/07/19
STFL
06/07/19
UPGRADE
Target $50
STFL
Buy
Schlumberger upgraded to Buy from Hold at Stifel
Stifel analyst Stephen Gengaro upgraded Schlumberger to Buy from Hold with an unchanged price target of $50. The company is generating "solid" free cash flow and the stock's risk/reward is "compelling" at current levels, Gengaro tells investors in a research note. Further, the company's $2.00 per share annual dividend is "safe" and investors are getting "paid to wait," adds the analyst. He believes Schlumberger is well positioned to benefit as activity rises outside North America.
06/27/19
GABE
06/27/19
INITIATION
GABE
Buy
Schlumberger initiated with a Buy at Gabelli
Gabelli analyst Simon Wong started Schlumberger with a Buy rating and private market value estimate of $55. The analyst sees "strong" competitive advantages and a "reasonable" valuation for Schlumberger. Further, the analyst points out that should international and offshore recover faster than his projections, his 2023 private market value estimate of $75 can potentially reach $100 per share.

TODAY'S FREE FLY STORIES

LCI

Lannett

$7.82

-0.61 (-7.24%)

09:47
07/23/19
07/23
09:47
07/23/19
09:47
Hot Stocks
Lannett falls -5.1% »

Lannett is down -5.1%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NL

NL Industries

$4.80

(0.00%)

09:47
07/23/19
07/23
09:47
07/23/19
09:47
Hot Stocks
NL Industries falls -6.6% »

NL Industries is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JE

Just Energy

$3.94

-0.44 (-10.05%)

09:47
07/23/19
07/23
09:47
07/23/19
09:47
Hot Stocks
Just Energy falls -11.4% »

Just Energy is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PII

Polaris Industries

$87.80

5.265 (6.38%)

09:47
07/23/19
07/23
09:47
07/23/19
09:47
Hot Stocks
Polaris Industries rises 6.4% »

Polaris Industries is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

EDU

New Oriental Education

$104.82

6.585 (6.70%)

09:47
07/23/19
07/23
09:47
07/23/19
09:47
Hot Stocks
New Oriental Education rises 6.4% »

New Oriental Education is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

RLGY

Realogy

$6.61

1.44 (27.85%)

09:47
07/23/19
07/23
09:47
07/23/19
09:47
Hot Stocks
Realogy rises 28.2% »

Realogy is up 28.2%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

MGLN

Magellan Health

$68.15

(0.00%)

09:46
07/23/19
07/23
09:46
07/23/19
09:46
Periodicals
Magellan Health talks with Centerbridge hung up on price, Dealreporter says »

Centerbridge Partners and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HOG

Harley-Davidson

$33.01

-1.24 (-3.62%)

09:45
07/23/19
07/23
09:45
07/23/19
09:45
Hot Stocks
Harley-Davidson CEO says profit margins to recover in FY20 with fixed EU tariffs »

Harley-Davidson CEO Matt…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

09:45
07/23/19
07/23
09:45
07/23/19
09:45
General news
Richmond Fed Manufacturing Index Level to be reported at 10:00 »

July Richmond Fed…

09:45
07/23/19
07/23
09:45
07/23/19
09:45
General news
Existing Home Sales to be reported at 10:00 »

June Existing Home Sales…

CURLF

Curaleaf Holdings

$0.00

(0.00%)

09:40
07/23/19
07/23
09:40
07/23/19
09:40
Hot Stocks
FDA sends warning letter to Curaleaf over unapproved, 'misbranded' drugs »

The FDA posted on its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ETN

Eaton

$79.54

(0.00%)

, SHLAF

Schindler

$0.00

(0.00%)

09:40
07/23/19
07/23
09:40
07/23/19
09:40
Hot Stocks
Eaton appoints Silvio Napoli to board of directors »

Eaton (ETN) announced…

ETN

Eaton

$79.54

(0.00%)

SHLAF

Schindler

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

AZN

AstraZeneca

$40.32

(0.00%)

, GM

General Motors

$39.86

(0.00%)

09:40
07/23/19
07/23
09:40
07/23/19
09:40
Options
Unusually active option classes on open July 23rd »

Unusual total active…

AZN

AstraZeneca

$40.32

(0.00%)

GM

General Motors

$39.86

(0.00%)

WHR

Whirlpool

$148.30

(0.00%)

HAS

Hasbro

$108.54

(0.00%)

KO

Coca-Cola

$51.25

(0.00%)

BIIB

Biogen

$232.46

(0.00%)

LMT

Lockheed Martin

$357.57

(0.00%)

ABT

Abbott

$88.08

(0.00%)

BYND

Beyond Meat

$193.91

(0.00%)

NVDA

Nvidia

$171.32

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 25

    Jul

  • 29

    Jul

  • 01

    Aug

  • 03

    Aug

  • 12

    Aug

  • 15

    Aug

  • 09

    Sep

  • 16

    Sep

  • 19

    Sep

  • 25

    Sep

  • 02

    Oct

  • 23

    Oct

09:40
07/23/19
07/23
09:40
07/23/19
09:40
General news
U.S. existing home sales preview: analysts expect a steady rate for June existing home sales »

U.S. existing home sales…

CABO

Cable One

$1,206.29

-11.71 (-0.96%)

09:38
07/23/19
07/23
09:38
07/23/19
09:38
Upgrade
Cable One rating change at Wolfe Research »

Cable One upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MFSF

MutualFirst Financial

$32.20

0.28 (0.88%)

09:37
07/23/19
07/23
09:37
07/23/19
09:37
Earnings
MutualFirst Financial reports Q2 EPS 66c, consensus 62c »

The Company's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVM

CEL-SCI

$6.22

-0.38 (-5.76%)

09:35
07/23/19
07/23
09:35
07/23/19
09:35
Hot Stocks
CEL-SCI announces review published in International Immunopharmacology »

CEL-SCI Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UTX

United Technologies

$132.94

0.57 (0.43%)

09:33
07/23/19
07/23
09:33
07/23/19
09:33
Hot Stocks
United Technologies says 'very confident' about updated FY19 guidance »

Says: More good things to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

PKX

Posco

$49.91

-0.26 (-0.52%)

09:33
07/23/19
07/23
09:33
07/23/19
09:33
Upgrade
Posco rating change at Macquarie »

Posco upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

TRPX

Therapix Biosciences

$2.32

-0.02 (-0.85%)

09:33
07/23/19
07/23
09:33
07/23/19
09:33
Hot Stocks
Therapix Biosciences signs LOI to merge with Destiny Biosciences »

Therapix Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,985.93

21.15 (1.08%)

09:32
07/23/19
07/23
09:32
07/23/19
09:32
Recommendations
Amazon.com analyst commentary at BMO Capital »

Amazon.com Q3 consensus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

UGP

Ultrapar

$5.23

-0.165 (-3.06%)

09:32
07/23/19
07/23
09:32
07/23/19
09:32
Upgrade
Ultrapar rating change at Bradesco »

Ultrapar upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HOG

Harley-Davidson

$34.25

-0.62 (-1.78%)

09:31
07/23/19
07/23
09:31
07/23/19
09:31
Hot Stocks
Breaking Hot Stocks news story on Harley-Davidson »

Harley-Davidson sees Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

SEMG

SemGroup

$11.92

0.13 (1.10%)

09:31
07/23/19
07/23
09:31
07/23/19
09:31
Upgrade
SemGroup rating change at Citi »

SemGroup upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Aug

HOG

Harley-Davidson

$34.25

-0.62 (-1.78%)

09:28
07/23/19
07/23
09:28
07/23/19
09:28
Hot Stocks
Harley-Davidson continues to see FY19 annual cash savings of $25M-$30M »

Sees FY20 annual cash…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.